Description
Survodutide (BI 456906) is a synthetic peptide engineered as a dual agonist at the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R). Unlike selective GLP-1 receptor agonists, survodutide combines the appetite-suppressing and insulinotropic effects of GLP-1R activation with the energy expenditure-promoting and hepatic lipid-lowering effects of glucagon receptor activation. It is currently in Phase 3 clinical development by Boehringer Ingelheim for obesity and MASH (metabolic dysfunction-associated steatohepatitis).
This product is supplied as a sterile lyophilized powder and is intended strictly for research purposes only. It is NOT for human or veterinary consumption.
Key Research Focus
Survodutide has been investigated in preclinical and clinical research exploring its roles in:
- Dual Receptor Pharmacology and Central Mechanism of Action: Preclinical research demonstrates that survodutide directly accesses circumventricular organs (CVOs) and adjacent hypothalamic and hindbrain nuclei without uniformly crossing the blood-brain barrier. c-Fos labeling confirms activation of multiple nuclei associated with food intake control. Notably, GCGR expression is barely detectable in the area postrema and arcuate nucleus, while GLP1R is expressed in these tissues. A long-acting GCGR agonist alone did not induce neuronal activation in satiety-mediating regions nor reduce food intake, supporting the hypothesis that survodutide’s intake-suppressive effects are GLP-1R dependent .
- Weight Reduction (Phase 3 SYNCHRONIZE-1): In a Phase 3 trial of 725 adults with obesity without diabetes, survodutide produced mean body weight reductions of –12.2% (3.6 mg) and –13.0% (6.0 mg) at week 76, compared to –5.4% with placebo (treatment-regimen estimand). Weight reduction of ≥5% was achieved by 72.6% and 71.9% of participants in the 3.6 mg and 6.0 mg groups, respectively, versus 46.3% with placebo. Up to 16.6% weight loss was reported in responder analyses .
- Metabolic Health Benefits: The SYNCHRONIZE-1 trial demonstrated visceral fat reductions of up to 34% and liver fat reductions of up to 63.1% . In the SYNCHRONIZE-MASLD trial of adults with MASLD, survodutide was associated with a mean 12.2% weight loss (versus –1.0% placebo), and 84.2% of participants achieved ≥30% reduction in liver fat (versus 24.3% with placebo, odds ratio 17.3; p<0.0001) .
- MASH and Liver Fibrosis (Phase 2 Data): In a Phase 2 trial in people with MASH and fibrosis, improvement in fibrosis without worsening of MASH was observed in up to 64.5% of participants who took survodutide 6.0 mg versus 25.9% who took placebo. Survodutide was superior to placebo for improvement in MASH without worsening of fibrosis (p<0.001) . A Phase 3 trial (LIVERAGE) evaluating long-term efficacy in noncirrhotic MASH with F2–F3 fibrosis is ongoing, with an estimated primary completion date in 2031 .
- Beta-Cell Function and Insulin Sensitivity: A dedicated study evaluated survodutide’s effects on biomarkers of beta-cell function and insulin sensitivity in people with type 2 diabetes or overweight/obesity .
Safety Considerations (Clinical Trial Context)
- Gastrointestinal Adverse Events: The most common adverse events were gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), occurring in 80.9%–89.7% of survodutide-treated participants versus 47.9% with placebo. Events were typically mild to moderate but led to treatment discontinuation in 17.8%–20.2% of survodutide groups versus 2.9% with placebo .
- Serious Adverse Events: Serious adverse events were similar across groups (~8%), and no major adverse cardiovascular events occurred with survodutide in the SYNCHRONIZE-1 trial. No deaths were reported .
Product Specifications
- Form: Lyophilized Powder (Sterile)
- Purity: ≥95% (HPLC Verified)
- Storage: Store at -20°C (freezer) for long-term stability. Protect from light.
- Solubility: Soluble in sterile water or buffer for laboratory use.
- Disclaimer: This product is a chemical reagent for research purposes only. It is NOT for human or animal consumption, diagnostic, or therapeutic use.
Why Choose Survodutide?
Survodutide offers a mechanistically distinct research tool for studying dual GCGR/GLP-1R activation, a strategy that may provide complementary benefits beyond selective GLP-1 receptor agonism. Its demonstrated effects on body weight, visceral fat, and liver fat in Phase 3 trials, combined with evidence of direct hepatic effects that are partially independent of weight loss, make it valuable for research into integrated metabolic regulation, MASH pathophysiology, and energy homeostasis . Researchers should note the significant gastrointestinal tolerability burden observed in clinical trials and the ongoing nature of Phase 3 development for MASH endpoints.



